Nikki J. Wagner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nikki J. Wagner has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Sarah Elizabeth Rowe
Department of Microbiology and Immunology, University of North Carolina
3 shared publications - Brian Patrick Conlon
Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
2 shared publications Amanda Z. Velez
Department of Microbiology and Immunology, University of North Carolina
1 shared publicationBenjamin I. Morris
Department of Microbiology, Harvard Medical School, Boston, MA, USA
1 shared publicationBrian Hardy
Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1 shared publicationElias P. Rosen
Eshelman School of Pharmacy, University of North Carolina
1 shared publication
Latest Publications
- Open Access
- 14 January 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (3)
The innate immune protein calprotectin ablates the bactericidal activity of β-lactam antibiotics
β-lactam antibiotics are among the most widely used treatments for bacterial infections, yet therapeutic failure is common even when no genetic resistance is detected. Understanding how host factors influence antibiotic efficacy is critical for improving outcomes. Here, we identify a host-derived mechanism of antibiotic tolerance mediated by calprotectin (CP), a zinc-binding protein released in large quantities by neutrophils during infection. We show that CP induces tolerance to β-lactam antibiotics in Staphylococcus aureus by chelating zinc and inactivating autolysins, zinc-dependent enzymes required for cell wall degradation and bacterial lysis following β-lactam treatment. This protective effect was specific to β-lactam antibiotics at concentrations of CP showing minimal impact on bacterial growth or metabolic state. Mechanistic studies revealed that CP inhibits the autolytic activity of Atl, the major S. aureus autolysin, by depriving the enzyme of its zinc cofactor. In a murine infection model, the efficacy of oxacillin was significantly enhanced in CP-deficient mice, demonstrating that CP impairs β-lactam activity in vivo. These findings reveal a form of immune-mediated antibiotic tolerance driven by metal sequestration and suggest that zinc availability at infection sites plays a critical role in shaping treatment outcomes.
- 14 January 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (3)
Open AccessThe innate immune protein calprotectin ablates the bactericidal activity of β-lactam antibiotics
β-lactam antibiotics are among the most widely used treatments for bacterial infections, yet therapeutic failure is common even when no genetic resistance is detected. Understanding how host factors influence antibiotic efficacy is critical for improving outcomes. Here, we identify a host-derived mechanism of antibiotic tolerance mediated by calprotectin (CP), a zinc-binding protein released in large quantities by neutrophils during infection. We show that CP induces tolerance to β-lactam antibiotics in Staphylococcus aureus by chelating zinc and inactivating autolysins, zinc-dependent enzymes required for cell wall degradation and bacterial lysis following β-lactam treatment. This protective effect was specific to β-lactam antibiotics at concentrations of CP showing minimal impact on bacterial growth or metabolic state. Mechanistic studies revealed that CP inhibits the autolytic activity of Atl, the major S. aureus autolysin, by depriving the enzyme of its zinc cofactor. In a murine infection model, the efficacy of oxacillin was significantly enhanced in CP-deficient mice, demonstrating that CP impairs β-lactam activity in vivo. These findings reveal a form of immune-mediated antibiotic tolerance driven by metal sequestration and suggest that zinc availability at infection sites plays a critical role in shaping treatment outcomes.
- Open Access
- 26 November 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (48)
Antibiotics accumulate in Klebsiella pneumoniae liver abscesses but fail to eliminate antibiotic-tolerant populations
Liver abscesses caused by hypervirulent Klebsiella pneumoniae (hvKp) can lead to severe metastatic complications, with mortality rates ranging from 5 to 40%. Even in the absence of antibiotic resistance, hvKp liver abscesses often respond poorly to treatment, sometimes requiring surgical resection. The reason for these poor outcomes remains unknown. Here, we established an hvKp wound model in outbred immunocompetent mice, which progresses to systemic infection and hepatic abscesses that were intractable to antibiotic therapy. Using a combination of quantitative and infrared matrix-assisted laser desorption electrospray ionization imaging mass spectrometry, we found that antibiotics fail to kill K. pneumoniae in liver abscesses, independently of resistance or spatial distribution of antibiotics. Our results show that antibiotic concentrations detected in the liver are sufficient to eradicate hvKp under standard in vitro conditions, but the continued presence of viable bacteria in vivo indicates that hvKp adopts an antibiotic-tolerant state within the liver. Notably, the inadequate antibiotic efficacy observed in our mouse studies mirrors clinical outcomes. These findings underscore the urgent need to elucidate the mechanism underlying hvKp tolerance, which could inform the development of novel therapeutic approaches.
- 26 November 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (48)
Open AccessAntibiotics accumulate in Klebsiella pneumoniae liver abscesses but fail to eliminate antibiotic-tolerant populations
Liver abscesses caused by hypervirulent Klebsiella pneumoniae (hvKp) can lead to severe metastatic complications, with mortality rates ranging from 5 to 40%. Even in the absence of antibiotic resistance, hvKp liver abscesses often respond poorly to treatment, sometimes requiring surgical resection. The reason for these poor outcomes remains unknown. Here, we established an hvKp wound model in outbred immunocompetent mice, which progresses to systemic infection and hepatic abscesses that were intractable to antibiotic therapy. Using a combination of quantitative and infrared matrix-assisted laser desorption electrospray ionization imaging mass spectrometry, we found that antibiotics fail to kill K. pneumoniae in liver abscesses, independently of resistance or spatial distribution of antibiotics. Our results show that antibiotic concentrations detected in the liver are sufficient to eradicate hvKp under standard in vitro conditions, but the continued presence of viable bacteria in vivo indicates that hvKp adopts an antibiotic-tolerant state within the liver. Notably, the inadequate antibiotic efficacy observed in our mouse studies mirrors clinical outcomes. These findings underscore the urgent need to elucidate the mechanism underlying hvKp tolerance, which could inform the development of novel therapeutic approaches.
- Open Access
- 10 October 2025
- Published by Springer Nature in Nature Microbiology
- Vol. 10 (11) , 3013-3025
A host-directed adjuvant sensitizes intracellular bacterial persisters to antibiotics
Intracellular bacterial reservoirs contribute to antibiotic treatment failure by fostering metabolically dormant persister cells that are highly tolerant to killing. However, strategies to effectively target intracellular persister cells remain limited. Here we developed a high-throughput screen to identify compounds that modulate the metabolic activity of intracellular Staphylococcus aureus . The identified compound, KL1, increases intracellular bacterial metabolic activity and sensitizes persister populations of S. aureus to antibiotics, without causing cytotoxicity or bacterial outgrowth. KL1 also exhibits adjuvant activity against intramacrophage Salmonella enterica Typhimurium and Mycobacterium tuberculosis , as well as in murine infection models of S. aureus and S . Typhimurium infection. Transcriptomic analysis and further mechanistic studies reveal that KL1 modulates host immune response genes and suppresses the production of reactive species in host macrophages, alleviating a key inducer of antibiotic tolerance. Our findings highlight the potential to target intracellular persisters by stimulating their metabolism. There are two major problems in the field of antimicrobial chemotherapy–antibiotic resistance and antibiotic tolerance. Antibiotic tolerance has been frequently connected with poor treatment outcomes in the clinic. Unlike antibiotic resistance, which permits bacterial growth in the presence of drugs, antibiotic tolerance allows bacteria to withstand multiple antibiotics for prolonged periods. The extended survival of tolerant bacteria further predisposes them to evolve antibiotic resistance over time, underscoring the critical need to address antibiotic tolerance. Host interactions have been shown to induce persister formation in numerous pathogens, with the production of reactive oxygen and nitrogen species heavily implicated in the collapse of bacterial metabolic activity and entry into an antibiotic-tolerant state. Yet, tools to study or target this process remain limited. Here we developed a high-throughput screen to identify compounds that modulate intracellular S. aureus metabolism, leading to the discovery of KL1, a host-directed compound that sensitizes persisters to antibiotic killing.
- 10 October 2025
- Published by Springer Nature in Nature Microbiology
- Vol. 10 (11) , 3013-3025
Open AccessA host-directed adjuvant sensitizes intracellular bacterial persisters to antibiotics
Intracellular bacterial reservoirs contribute to antibiotic treatment failure by fostering metabolically dormant persister cells that are highly tolerant to killing. However, strategies to effectively target intracellular persister cells remain limited. Here we developed a high-throughput screen to identify compounds that modulate the metabolic activity of intracellular Staphylococcus aureus . The identified compound, KL1, increases intracellular bacterial metabolic activity and sensitizes persister populations of S. aureus to antibiotics, without causing cytotoxicity or bacterial outgrowth. KL1 also exhibits adjuvant activity against intramacrophage Salmonella enterica Typhimurium and Mycobacterium tuberculosis , as well as in murine infection models of S. aureus and S . Typhimurium infection. Transcriptomic analysis and further mechanistic studies reveal that KL1 modulates host immune response genes and suppresses the production of reactive species in host macrophages, alleviating a key inducer of antibiotic tolerance. Our findings highlight the potential to target intracellular persisters by stimulating their metabolism. There are two major problems in the field of antimicrobial chemotherapy–antibiotic resistance and antibiotic tolerance. Antibiotic tolerance has been frequently connected with poor treatment outcomes in the clinic. Unlike antibiotic resistance, which permits bacterial growth in the presence of drugs, antibiotic tolerance allows bacteria to withstand multiple antibiotics for prolonged periods. The extended survival of tolerant bacteria further predisposes them to evolve antibiotic resistance over time, underscoring the critical need to address antibiotic tolerance. Host interactions have been shown to induce persister formation in numerous pathogens, with the production of reactive oxygen and nitrogen species heavily implicated in the collapse of bacterial metabolic activity and entry into an antibiotic-tolerant state. Yet, tools to study or target this process remain limited. Here we developed a high-throughput screen to identify compounds that modulate intracellular S. aureus metabolism, leading to the discovery of KL1, a host-directed compound that sensitizes persisters to antibiotic killing.